Research progression on resistance mechanisms of epidermal growth factor receptor tyrosine kinase ;inhibitors in non-small cell lung cancer / 国际肿瘤学杂志
Journal of International Oncology
;
(12): 206-209, 2015.
Article
Dans Chinois
| WPRIM
| ID: wpr-465047
ABSTRACT
EGFR-TKI plays an important role in the treatment of non-small-cell lung cancer. However, some researchers find that there are still some patients with primary or acquired resistance to EGFR-TKI. The present known mechanisms of acquired drug resistance finally lead to the re-activation EGFR downstream signa-ling pathways. Liver X receptor agonist has inhibition function to several critical steps of EGFR downstream sig-naling pathways PI3K-Akt-NF-κB,which makes it possible to overcome the drug resistance.
Texte intégral:
Disponible
Indice:
WPRIM (Pacifique occidental)
langue:
Chinois
Texte intégral:
Journal of International Oncology
Année:
2015
Type:
Article
Documents relatifs à ce sujet
MEDLINE
...
LILACS
LIS